MAPT and Alzheimer disease: reprogramming fibroblasts from AD patients into iPSCs, which then differentiate into neurons, will be able to recapitulate typical pathological phenomena such as Aβ plaque formation, tau tangles, and so on, in vitro, and give a precise model for drug screening (Schulz, 2021; Yefroyev and Jin, 2022).